CRBU CARIBOU BIOSCIENCES INC

Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in the following investor conferences:

  • H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

    February 25, 2025, fireside chat at 11:30 AM ET

  • Leerink Global Healthcare Conference

    March 11, 2025, fireside chat at 1:40 PM ET

For more information, visit the page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.

About Caribou Biosciences, Inc.

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit .

Caribou Biosciences, Inc. contacts:

Investors:

Amy Figueroa, CFA

 

Media:

Peggy Vorwald, PhD

 



EN
18/02/2025

Underlying

CRBUCARIBOU BIOSCIENCES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CARIBOU BIOSCIENCES INC

 PRESS RELEASE
Free
CRBU CARIBOU BIOSCIE...

Caribou Biosciences Announces Strategic Pipeline Prioritization with F...

Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs -- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company’s cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 now expected to be disclosed in H2 2025 -- -- CB-010 ANTLER 2L LBCL Phase 1 dataset expected to include at least six months of follow up on the majority of patients; ongoing interactions with FDA on potential pivotal trial design -- -- CB-011 CaMMouflage r/r MM Phase 1 dose escal...

14h / 29m 1 EN
 PRESS RELEASE
Free
CRBU CARIBOU BIOSCIE...

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financia...

Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update -- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 -- -- Advancing four clinical programs for hematologic malignancies and autoimmune diseases -- -- $249.4 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current operating plan into H2 2026 -- BERKELEY, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharm...

March 10, 2025 1 EN
 PRESS RELEASE
Free
CRBU CARIBOU BIOSCIE...

Caribou Biosciences to Participate in Upcoming Investor Conferences

Caribou Biosciences to Participate in Upcoming Investor Conferences BERKELEY, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in the following investor conferences: H.C. Wainwright 3rd Annual Cell Therapy Virtual ConferenceFebruary 25, 2025, fireside chat at 11:30 AM ET Leerink Global Healthcare ConferenceMarch 11, 2025, fireside chat at 1:40 PM ET For more information, visit the page on Caribou’s w...

February 18, 2025 1 EN
 PRESS RELEASE
Free
CRBU CARIBOU BIOSCIE...

Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus...

Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025 -- CB-010 GALLOP Phase 1 trial initiated in lupus -- -- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 -- -- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 -- -- Sri Ryali appointed chief financial officer -- -- Caribou to present at 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, at 10:30 am PST -- BERKELEY, Calif., Jan. 1...

January 13, 2025 1 EN
 PRESS RELEASE
Free
CRBU CARIBOU BIOSCIE...

Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare C...

Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference BERKELEY, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, is scheduled to present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 am PST. For more information and a link to the live , visit the page on Caribou’s website. Webcasts will be available ...

January 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch